Presentations


Xbrane Company Presentation February 2022

Xbrane Company Presentation

Press Releases

11 Nov 2022

STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®

31 Oct 2022

Change of number of shares and votes in Xbrane

28 Oct 2022

Presentation of Xbrane Biopharma’s interim report January – September 2022 on October 28, 2022

28 Oct 2022

Xbrane Biopharma releases interim report for January – September 2022

26 Oct 2022

Invitation to presentation of Xbrane Biopharma’s interim report January – September 2022 on October 28, 2022

20 Oct 2022

Xbrane Biopharma presents Nomination Committee

18 Oct 2022

Xbrane has carried out a directed share issue raising gross proceeds of approximately SEK 170 million

18 Oct 2022

Xbrane announces intention to carry out a directed share issue

19 Sep 2022

By reason of the imminent launch of Ximluci® in Europe, Xbrane Biopharma AB invites to a Capital Markets Day on September 22, 2022

Financial Reports

18 Apr 2013

Annual report 2013 (available in Swedish only)

18 Apr 2014

Annual report 2014 (available in Swedish only)

31 Dec 2015

Annual report 2015 (available in Swedish only)

18 Dec 2015

Year-end report 2015 (available in Swedish only)

18 Apr 2015

Interim report January – September 2015 (available in Swedish only)

Financial Calendar

17 Feb 2023

Year-end report 2022

31 Mar 2023

Annual report 2022

04 May 2023

Annual General Meeting 2023

31 Aug 2023

Interim report January – June 2023

31 May 2023

Interim report January – March 2023

Contact Investor Relations

Anette Lindqvist, CFO & Head of Investor Relation

Presentations and media


PRESENTATION AT PARETO HELTHCARE CONFERENCE

September 3, 2020

Presentation at LSX Nordic Congress

August 29, 2019

Presentation at BioStock Live

March 20, 2019